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Blessed with extremely rich biodiversity, Malaysia is all geared up to explore new 
high  technology  to  utilize the  advantage  it  possesses whilst  to  protect its environment. 
Biotechnology has been identified as an appropriate driver that can deliver economic gains 
through  research  and  development,  improvement  of  food  security,  creation  of 
entrepreneurial  opportunities  for  industrial  growth,  health  and  environmental 
sustainability. This paper attempts to address the evolution of biotechnology institutions 
and the stumbling blocks in developing the Malaysian biotechnology industry. This paper 
identifies three main impediments in the current Malaysian biotechnology, namely lack of 
skilled human capital; weak industrial base; and lack of commercialization effort. Besides, 
a set of strategies are discussed with aim to further improve and strengthen the Malaysian 
biotechnology  industry.  In  general,  the  arguments  are  presented  by  mapping  out  the 
symbiotic relationship between data from elite interviews, archival data and observations. 
 




Dotatǎ  cu  o  biodiversitate  extrem  de  bogatǎ,  Malaezia  este  orientatǎ  spre 
explorarea noilor tehnologii înalte pentru a utiliza avantajul de care dispune şi în acelaşi 
timp, pentru a proteja mediul său. Biotehnologia a fost identificată ca un driver adecvat, 
care  poate  asigura  câştiguri  economice  prin  cercetare  şi  dezvoltare,  îmbunătăţirea 
securităţii  alimentare,  crearea  de  oportunităţi  de  antreprenoriat  pentru  creşterea 
industrialǎ si un mediu sănătos şi durabil. Această lucrare încearcă să abordeze evoluţia 
instituţiilor  de  biotehnologie  şi  obstacolele  în  dezvoltarea  industriei  biotehnologiei  din 
Malaiezia.  Acest  document  identifică  trei  obstacole  principale în  biotehnologia  actualǎ 
malaiezianǎ, şi anume: lipsa de capital uman calificat; baza industrialǎ slabă; şi lipsa 
efortului de marketing. În plus, sunt discutate un set de strategii cu scopul de a îmbunătăţi 
şi consolida în continuare industria biotehnologiei malaeziane. În general, argumentele 
sunt prezentate prin cartografierea relaţiei simbiotice între datele de la interviurile de elită, 
datele arhivate şi observaţii. 
 
Cuvinte-cheie:  industria  biotehnologicǎ  din  Malaezia,  capitalul  uman,  baza 
industrialǎ, comercializare. 
 











n the last 50 years, Malaysian economy has been transformed from a 
protected low income supplier of raw materials to a middle income 
emerging  multi-sector  market  economy  driven  by  manufactured 
exports, particularly electronics and semiconductors. The transition of Malaysian 
economy  is  a  fascinating  story  with  a  dramatic  history  that  challenges  many 
conventional models of national development. During the pre-independence period, 
Malaysian economy was largely dependent on mining, agriculture and plantation. 
In plantation industry, rubber was one of the most sought after product, in regard of 
the development of automobile industry in industrial countries, especially in the 
United  States  (Drabble,  2000).  Hence  the  rubber  industry,  combined  with 
expansion  of  tin  mining  industry,  made  Malaysia  one  of  the  most  prosperous 
economy of the era. 
  After independence, Malaysian economy moved into a rapid development 
zone, especially in the 1960s, where the traditional export economy was renewed 
by a very successful program of replanting rubber estates and production of palm 
oil. In the 1970s and 1980s, the most important source of Malaysian economic 
growth has been the development of a substantial oil and natural gas industry.
1 
During  the  same  period  of  time,  Malaysia  followed  the  footsteps  of  the  Asian 
Tigers (Singapore, Hong Kong and South Korea) and committed itself to transition 
from  reliance  on  mining  and  agriculture  to  manufacturing,  particularly  in 
electronics and textiles.
2 With Japan’s assistance, Malaysia’s manufacturing and 
heavy industries flourished in a matter of years. As a result, Malaysia experienced 
one of the highest growth rates of about 8 percent per annum from the mid-1980s 
until 1997 before the country was hit with the Asian economic crisis. However, it 
rebounded commendably, registering annual growth ranging from 4 to 5% since 
1999.
3 
In the new millennium, biotechnology along with information technology 
has emerged as a powerful technology that shows big potential for a number of 
economic sectors. The convergence of these new technologies provides a greater 
opportunity to develop better strategies and approaches to deal with current and 
future  economic  challenges  in  the  fields  like  agriculture,  medicine,  food 
processing, environmental protection, mining, and even nanoelectronics (Zylstraa 
and Kukor, 2005). Besides, biotechnology has proven to be an industry that able to 
generate huge amount of revenues. For instance, the global biotech industry grew 
by 10.6% in 2007 to reach a value of RM611.6 billion. And by 2012, the market is 
forecasted to have a value of RM983.5 billion, an increase of 60.5% than 2007.
4 
While in Malaysia, the global research house Frost & Sullivan predicted that the 
biotechnology industry would able to generate RM45 billion in revenues by 2013, 
at  an  average  rate  of  15  per  cent  annually.
5  This  certainly  has  prompted  the 
Malaysian  Government  to  recognise  biotechnology  as  one  of  the  key  strategic 
drivers  that  will  propel  the  nation’s  social  and  economic  development  further. 
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Furthermore, biotechnology is expected to expand societal well being and wealth 
creation  by  unlocking  the  value  of  the  country’s  natural  resources  and  human 
capital talents. 
 
Importance of biotechnology to Malaysia 
 
IBISWorld  in  its  Global  Biotechnology  Industry  report  defined 
biotechnology as “The application of science and technology to living organisms as 
well as parts, products, models thereof, to alter living or non-living materials for 
the production of knowledge, goods and services”.
6 Actually, biotechnology is not 
something new as it has been practiced since thousands of years ago, for instance 
using yeast in bread, beer and wine production. Furthermore, bacteria were used to 
extract minerals from ore, in agriculture and manufacturing industry to produce 
food, chemicals, medicines and many other products that have been of benefit in 
many areas including nutrition, and human and animal health (Duffy, 2001). Over 
the time, this technology was further improved through the use of more advanced 
techniques of modern biotechnology which can be used to enhance both quality 
and quantity of the product (Maliro, 2001). 
In Malaysia, biotechnology, by virtue of its nature, has much to offer for 
the sustainable development in agriculture, environment, bio-industries and other 
sectors. Since Malaysia is an agriculture country, there is a real need to engage 
biotechnology  to  avoid  losing  boat  with  bigger  industrial  players.  Today,  the 
agricultural  sector  contributes  about  9.7  percent  to  the  overall  gross  domestic 
product (GDP) of Malaysia.
7 However, the Malaysian agricultural sector is facing 
two  major  challenges.  The  first  are  in  the  realm  of  addressing  national  food 
security,  as  to  produce  sufficient  amount  of  food  to  meet  the  national  needs.
8 
Currently,  the  country  is  unable  to  produce  sufficient  amount  of  food  for  the 
population, which led to an increase in the import of food. For instance, local rice 
production  are  only  capable  to  cater  approximately  60-65%  of  domestic 
requirements.
9  Therefore,  the  shortfall  is  being  supplemented  by  imported  rice 
from other countries like Thailand and Philippines. According to a respondent, the 
second  major  challenge  is  related  to  creating  wealth  for  the  nation  through 
production of value added food and food products, which are more competitive in 
the open market, and to support the manufacturing sector through production of 
sufficient  amount  of  raw  materials.  Hence,  a  crucial  injection  of  new  high 
technology is required to transform the agricultural sector to be more productive 
especially in meeting the specified two challenges. 
Besides, Malaysia is blessed with rich biodiversity and natural resources 
that are useful as a basis for the biotechnology research and development (R&D). 
In  fact,  Malaysia  is  ranked  12th  in  the  mega-diversity  countries,  creating  the 
necessary  motivation  to  develop  a  biotechnology  industry  (Badawi,  2007).
  The 
extremely rich biodiversity and natural resources indicates that Malaysia has a rich 
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of mammals, 150000 species of invertebrates with insects being the largest single 
group, 1200 species of butterflies, 12000 species of moths and over 8000 species of 
fishes (Latiff and Zakri, 2000). These genetic resources have long been a source of 
important raw materials in agriculture and medicine. The rapid advancement in 
biotechnology  has  increased  the  potential  uses  of  genetic  resources  and  their 
economic value. For example, the global bulk drugs industry which utilises genetic 
resources to develop new and improved drugs was estimated to be worth RM276.5 
billion  in  2005  and  is  expected  to  rise  at  a  compounded  annual  growth  rate 
(CAGR) of 10.6% by the end of 2009.
10 Furthermore, it has been reported that 33% 
of drug products in the highly industrialised countries are derived directly from 
plants and most of these are tropical plants growing in equatorial countries such as 
Malaysia (Jusoh, 2006). 
In  consideration  of  these  opportunities  and  challenges,  Malaysia  has 
certainly  identified  biotechnology  as  an  appropriate  vehicle  that  can  deliver 
economic  gains through  research  and  development.  With  the  strong backing  of 
natural resources, Malaysia is all set to venture into this high technology that are 
able to improve food security, promote the sustainable use of natural resources and 
at the same time create new business opportunity and employments. 
 
  Development of Biotechnology Institutions 
in Malaysia 
 
Generally,  biotechnology  development  in  Malaysia  can  be  categorized, 
(Figure 1), into four main phases; first phase was prior to 1995, second phase was 
from 1995-2000 and third phase was from 2001-2005 and fourth phase was beyond 
2006. The first phase of biotechnology development in Malaysia began with the 
establishment of basic infrastructures, necessary equipments and set up, in addition 
to basic expertise to undertake biotechnology research and development (R&D). In 
the  beginning,  number  of  research  institutions  such  as  Malaysian  Agricultural 
Research  and  Development  Institute  (MARDI),  Rubber  Research  Institute  of 
Malaysia (RRIM), Palm Oil Research Institute of Malaysia (PORIM), Universiti 
Putra  Malaysia  (UPM),  Universiti  Sains  Malaysia  (USM)  and  Universiti 
Kebangsaan Malaysia (UKM) were assigned to carry out the R&D.
10 Furthermore, 
a National Working Group on Biotechnology was set up under the Ministry of 
Science,  Technology  and  Environment  (MOSTE)  to  oversee  and  coordinate 
biotechnology activities in the country. 
During the second phase of development, implementation of the national 
agenda  on  biotechnology  was  further  enhanced  with  the  establishment  of  the 
National Biotechnology Directorate (NBD) under MOSTE. The objective of the 
directorate is to spearhead the development of biotechnology in Malaysia through 
research and related activities directed at commercializing biotechnology, and to 
establish  Malaysia  as  a  leading  centre  for  biotechnology  industry.  At  the  same 






Economia. Seria Management        Vol.13, Nr. 1/2010 
 
15 
established to  assist in  coordinating the National  Programme  in  Biotechnology; 
developing a network among universities, research institutions and industries, and 
accelerate the diffusion of knowledge to the relevant industry. Besides the BCC 
system,  another  mechanism  called  the  Contact  Group  Programme  was  also 
established  by  NBD  to  facilitate  direct  communication  and  linkage  with 
participating institutions of the public and the private sectors. 
During  the  third  phase  of  development,  MOSTE  proposed  the 
establishment  of  three  national  institutes  that  specializes  in  R&D  with  national 
strategic importance. But after further studies and research, the Ministry proposed 
that these institutes to be developed within a Malaysian Biotechnology Cluster, 
known as BioValley Malaysia that are expected to best assure the success of the 
institutes. Furthermore, the formation of BioValley was expected to accelerate the 
research  and  commercialization  of  technologies  that  are  crucial  for  the 
development of Malaysia's regional and global competitiveness in the industry. The 
BioValley  Strategic  Plan  was  developed  through  collaboration  between  the 
National  Biotechnology  Directorate  and  Massachusetts  Institute  of  Technology 
(MIT), through the Malaysia-MIT Biotechnology Partnership Program (MMBPP). 
A  joint  workshop  was  held  from  29  January  to  2  February  2001  which  was 
attended by fifty three Malaysian experts from research institutions, universities, 
and  industry.
12  The  plan  was  based  on  the  cluster  concept  where  groups  of 
specialized  companies  support  each  other  to  create  a  center  of  excellence. 
Companies  within  the  cluster  can  take  advantage  of  the  presence  of  physical 
infrastructures, facilities, human resource, entrepreneurship and sharing of ideas to 
enable them to compete at a global level.  
In  May  2003,  BioValley  was  launched  by  then  Prime  Minister,  Tun 
Dr.Mahathir  Mohammad.  But  soon  after  its  launch,  there  was  no  much 
development  or  progress  in  the  BioValley  as  expected.  Although  the  plan  was 
drawn up by famed Japanese architect Kisho Kurokawa, the project was shrouded 
by problems (Cyranosk, 2005). So much so that the plan had been overhauled and a 
new strategy unveiled. On April 28, 2005, the former Prime Minister of Malaysia, 
Tun  Abdullah  Ahmad  Badawi  launched  the  National  Biotechnology  Policy  to 
stimulate  the  biotechnology  sector  into  a  new  economic  engine  to  enhance 
prosperity  and  wellness  of  the  nation  by  2020.  To  implement  the  policy,  the 
Malaysian Biotechnology Corporation (MBC) was created as a one stop agency to 
spearhead  the  development  of  the  sector,  including  coordination  of  regulatory 
policy among different agencies. MBC is overseen by an Implementation Council 
and advised by an International Advisory Panel, both under the leadership of the 
Prime Minister of Malaysia. MBC, which come under the purview of the Ministry 
of Science, Technology and Innovation (MOSTI), are responsible to facilitate the 
market driven R&D and commerce via funding and industry development services; 
and catalyzing commercial spin offs to the private sector (Ahmad, 2005). As a 
continuous effort to develop biotechnology industry, government of Malaysia has 
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of  ‘centre  of  excellence’  throughout  the  country,  comprising  companies  and 
institutions which specialize in specific biotech subsectors (Yunus, 2006). As to 
date, three centres of excellence have been established as part of the BioNexus, 
namely  the  Centre  of  Excellence  for  Agro-biotechnology  (MARDI  and  UPM); 
Centre of Excellence for Genomic & Molecular Biology (UKM); and Centre of 
Excellence for Pharmaceuticals & Nutraceuticals (USM and UPM).  
The activities in the fourth phase of the development are best explained by 
the 9th Malaysia Plan (2006-2010) in particular, Chapter 6 of the Plan. Under the 
9th  Malaysia  Plan,  the  government  of  Malaysia  allocated  US$550  million  for 
biotechnology  development  (Abdullah,  2006).  The  government  recognizes  the 
importance  of  a  conducive  regulatory  framework  to  ensure  the  success  of  its 
biotechnology  endeavor.  In  this  regard,  the  promotion  of  foreign  and  domestic 
investments and close collaboration with foreign entities to access new technology, 
expertise and markets will be intensified. At the same time, efforts are being taken 
to  improve  the  Intelectual  Property  (IP)  policy  and  management  framework  in 
order to foster innovation and safeguard investment in the biotechnology sector. 
 
Stumbling-blocks in Malaysian Biotechnology 
 
From  a  public  policy  perspective,  we  are  still  really  in  the  world  of 
expectations  when  we  talk  about  biotechnology,  especially  in  Malaysia.  In 
Malaysia, the hype, expectations, and variations of prospect in biotechnology are 
often detailed in many different reports. However, the problem with biotechnology 
in Malaysia is that many of these expectations have not yet been realized except in 
very  small  ways.  According  to  interviewed  respondents,  although  the  National 
Biotechnology  Policy  was  well  documented,  the  problems  often  arise  in  the 
implementation stage. This is largely due to the lack of skilled human capital, lack 
of industrial bases and many research products have no commercialization values. 
Biotechnology is a multidisciplinary science and it is an area that needs 
high capacity of human resources to achieve substantial benefits. Biotechnologist 
apart from having a  good basic knowledge of basic molecular biology requires 
knowledge  in  bioinformatics,  information  technology,  engineering,  statistics, 
genetic epidemiology, business management, product development and legal issues 
(Puchooa,  2004).  Therefore,  thrust  five  of  the  National  Biotechnology  Policy 
(NBP) focuses on building human capital in biotechnology through education and 


















































Figure 1. History of biotechnology development in Malaysia 
 
Prior 1995: Initial Institutional Development 
Research Institutions: MARDI, PORIM (now 
MPOB), PRIM (now MRB) 




National Biotechnology Directorate  
Biotechnology Cooperative Centers (BCC)  Contact Group Programme 
1995 
Malaysia - MIT Biotechnology Partnership Program (MMBPP) 
Joint Workshop: Malaysian Experts from Research Institutions, 
Universities & Industry 
29 Jan-2 Feb 2001 
BioValley Strategic Plan 
BioValley Malaysia 
National Biotechnology Policy 
Malaysian Biotechnology 
Corporation (MBC) 
1. National Implementation Council 
2. International Advisory Panel 
National Biotechnology Division 
(BIOTEK) (formerly known as National 
Biotechnology Directorate) 
May 2003 
Did not perform well 
9
th Malaysian Plan (2006-2010) 
Improve Intellectual Property (IP) Policy & Management Framework 
Bionexus 
Creation 
Malaysian Biotechnology Information Centre (MABIC)  2000 
7
th Malaysian Plan (1996-2000) 
8
th Malaysian Plan (2001-2005) 






Vol.13, Nr. 1/2010          Economia. Seria Management 
 
18
However, the current statistics shows that there is an alarming shortage of skilled 
manpower trained in biotechnology. According to the figures released by MOSTI, 
there  were  only  507  students graduated with  minimum qualification  of  masters 
during the period of 8
th Malaysian Plan. 
 
Number of students graduated from top-down RMK-8 Research Project 
Table 1 
Priority    Graduates     
Areas  Post Doctoral  PhD  Master  Total 
 Animal   3  43  78  124 
 Plant  2  5  13  20 
 Food  -  8  26  34 
 Biopharmacy  -  16  49  65 
 Medical  -  28  58  86 
 Molecular Biology  2  32  95  129 
 Environment/industry  -  19  30  49 
 Total  7  151  349  507 
Source: BIOTEK, MOSTI (as May 2008) 
 
Human capital in terms of fresh undergraduates is definitely not lacking in 
Malaysia as there are many universities and private colleges offering biotechnology 
courses at undergraduate level. As a result, an average of 1900 students majoring in 
biotechnology or biotechnology related programmes graduates from public higher 
learning institutes every year (see Table 2). But despite the huge number of fresh 
graduates, biotechnology companies in Malaysia is facing problem in securing the 
right candidate to fill various job portfolios. This is because these fresh graduates 
are very much lacking in hands-on experience and incomprehensive in meeting the 
demands  of  biotechnology  companies.  A  respondent  acknowledged  that  the 
problem actually lies deep within the Malaysian tertiary education system which is 
still  practicing  the  traditional  approach  where  the  students  are  only  trained 
academically while missing out soft skills needed by the industry. Hence, we can 
say that the human capital management in Malaysia is not equilibrium with the 
biotech industry’s need and demand. 
Although the focus on building human capital in biotechnology is vital and 
crucial step to fuel the growth of biotech industry, the effort is considered waste 
without  having  a  strong  industrial  base.  Obviously,  Malaysia  is  lacking  in  this 
aspect which is important to absorb and train young scientist churned out from 
local and foreign universities. According to Malaysian Biotechnology Corporation 
(BiotechCorp),  there were only  13  public-listed  biotechnology  and  life-sciences 
companies in 2008, an increase of 18% than in 2007. At the same time, there were 
92 companies with Bionexus status and most of them are small and medium size 
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obvious with unimpressive market capitalization of RM 2.5 billion in 2007 and this 
figure decreased 32 percent in 2008 to RM1.7 billion.
13 
 
Students graduated from the Public Higher Learning Institutes (Biotechnology and 
biotechnology related programmes) 
Table 2 
    Academic    Session  
Field (B.Sc)  2005/06  2006/07 
 Biochemistry  69  51 
 Molecular Biology  0  0 
 Microbiology  41  74 
 Plant Biotechnology  33  23 
 Plant Science  162  183 
 Animal Science/ Zoology  25  44 
 Food Science  726  472 
 Marine Science  132  70 
 Bioinformatics  0  16 
 Genetic  33  15 
 Pharmacy/ Pharmacology  256  327 
 Biotechnology  268  266 
 Forensic Science  27  35 
 Biomedic  352  227 
Total  2124  1803 
Source: Ministry of Higher Education, Malaysia (MOHE) 
 
Comparing to Australian biotechnology industry, the market capitalization 
of the health sector alone has reached RM110.9 billion, with the life science sector 
in particular growing in value by 81 percent over the past five years. According to 
a  new  PriceWaterhouseCoopers  (PWC)  BioForum  biotech  industry  report,  the 
market  capitalization  of  the  111  Australian  life  science  companies  grew  from 
RM28.7 billion to RM52 billion representing an 81 percent increase.
14 According 
to a respondent, the relatively weak biotechnology industrial base in Malaysia is a 
result of interest clash between the
 scientists and investors. Biotechnology is a huge 
investment  industry  and  the  profits  can  only  be  enjoyed  after  few  years  of 
operation.  Investors  who  don’t  understand  the  complexity  of  the  biological 
processes often become disillusioned and not interested in this industry. Apart from 
that,  lack  in  number  of  locally  available  skilled  and  knowledge  workers  also 
shunned  away  the potential  investors,  who  are  willing  to  invest in  neighboring 
countries like Singapore despite a higher set up cost. 
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In Malaysia, many researches are conducted mainly at public universities 
and public research institutes. Although the volume of researches is encouraging, 
the number of research products with commercialization value is disappointing. 
One of the factors that lead to lower commercialization in Malaysia is the fact that 
most researches are funded by the government or governmental agencies with only 
0.68% university R&D funding coming from the industry as compared to the more 
advanced countries, such as Canada (11.8%), Germany (7.5%), UK (6.2%) and the 
USA  (5.5%)  (Jusoh,  2007).  Typically,  the  government  agencies  won’t  provide 
proper  guidelines  compared  to  industries,  which  helps  the  local  scientist  to 
commercialize  their  products  as  most  of  them  don’t  have  sufficient  knowledge 
about  business,  Intellectual  Properties  (IP),  and  marketing.  Furthermore, 
commercialization also depends on the intention of the patent owners. Some patent 
owners  apply  for  patents  to  protect  future  research  rather  than  seek 
commercialization. At the same time, some products such as pharmaceuticals may 
require  regulatory  approvals  from  relevant  authorities  and  this  process  can 
consume huge amount of money as well as time. As a result of bureaucracy, many 
scientists  tend  to  shun  away  even  if  their  research  products  have  high 
commercialization value.  
Comparison  of  the  product  commercialization  in  Malaysia  with  that  of 
other  countries  with  active  biotechnology  industry  suggests  that  the  lack  of 
connectivity between the universities and research institutes with industries may 
hinder  the  commercialization  activities.  Rasli  (2005)  acknowledged  that 
commercialization of R&D has not been traditionally a high priority of universities 
in Malaysia. During the 7
th and 8
th Malaysia Plans, only 5.1% out of 5232 R&D 
projects implemented were considered as having commercialization potential but 
none of them was commercialized on a national scale (Mokhtar, 2005). The key 
reason behind the poor university-industry linkage in Malaysia is due to the lack of 
biotechnology industrial base.  The  current  biotechnology  industries  in Malaysia 
prefer  to  be  labor  intensive  and  not  invest  into  R&D  in  technology  to  gain 
competitive  advantage.  A  respondent  states  that  even  though  universities  in 
Malaysia begin to realize the importance of product commercialization, the effort 
to date has been quite modest.  
Interviews with some of the prominent industrial players involved in the 
National  Biotechnology  Policy  making  process  revealed  that  apart  from  the 
problems mentioned above, the Malaysian government still unable to fine-tune a 
proper working  mechanism for the biotechnology industry. This is  due  to  over 
consultations with the different interest groups such as  academicians, scientists, 
and  investors  made  government  indecisive  to  make  bold decisions and  actions. 
Furthermore, some of the consultants engaged were foreign based and according to 
the  respondents,  these  consultants  taken  easy  way  to  reproduce  the  findings 
prepared  by  the  local  consultants  with  some  adjustments.  Although  the  foreign 
consultants have included new ideas and suggestions, the respondents clearly felt 
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environment  and  real  situation  about  Malaysian  biotechnology  industry.  Hence, 
many  of  the  suggestions  were  only  good  in  paper  and  impractical  in  the  real 
situation.  
 
Strategies to strengthen the biotechnology industry 
 
Although there are some hiccups in the current biotechnology sector in Malaysia, 
the government strongly regards biotechnology as a technology which is not only 
important  for  the  economical  well-being  but  also  for  a  clean,  efficient  and 
pollution-free  environment.  In  order  to  accomplish  the  full  potential  of 
biotechnology with significant impact on society, Malaysia should begin to create 
environment conducive for R&D and innovations to achieve the perceived agenda 
and objectives. There is severe need in dynamic adjustments, both at institutional 
as well as at social levels in Malaysia. But first and foremost, the government itself 
must change its approach and strategies in developing the biotechnology industry. 
All  this  while,  the  Malaysian  government  has  been  practicing  the 
‘functional  industrial  policy’  when  developing  the  biotechnology  industry.  The 
‘functional industrial policy’ refers to a policy by which the state confines itself to 
stimulating  an  ideal  market  by  fulfilling  general  economic  functions  (Haque, 
2007).  Contrary  to  much  developed  countries  like  Japan  and  Singapore,  their 
biotechnology  industry  was  developed  through  the  ‘sectoral  industrial  policy’ 
approach.  The  ‘sectoral  industrial  policy’  refers  to  a  policy  by  which  the  state 
directs  resources  to  targeted  industries  identified  as  crucial  for  their  future 
competitiveness (Nolan and Pack, 2003). For a developing country with limited 
capital and relatively small market size, it is sometime argued that Malaysia should 
begin to concentrate and support its biotechnology industry to achieve sufficient 
economies of scale to compete in world markets, and then use the benefits of the 
industry  to  stimulate  other  domestic  sectors.  In  another  word,  Malaysia  should 
adopt  a  sectoral  industrial  policy  to  subsidise  technological  upgrading;  to  help 
industrial players move away from low-tech production and areas of established 
competitiveness. However, the effectiveness of a sectoral industrial policy is very 
much depends on the ability of government, which is shaped by socio-political 
factors  such  as  the  internal  working  mechanism  of  a  government  and  its 
interactions with various interest groups.  
In this aspect, Malaysia should look at Singapore’s ability in developing 
their  biotechnology  industry.  Lacking  in  natural  resources  and  land  supply  as 
compared to Malaysia, Singapore has fewer alternatives but to commit to higher 
value-added  industry  such  as  biotechnology.  Despite  a  small  domestic  market, 
Singapore was focused in facilitate and support its biotechnology endeavor. Part of 
its sectoral effort, Singapore government directed the universities, especially the 
science  and  engineering  departments  to  orientate  toward  market-driven 
technological  research  and  international  linkages.  As  Singapore  was  lacking  in 
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industry. Besides, the government contributed substantial financial support to train 
undergraduate and post-graduate in the field of bioscience. Many schemes were 
established to support personnel from the industry and academic for taking short 
courses and research attachments overseas; and to encourage companies to send 
employees to local universities to work on projects for technological learning (Tan 
and Byrne, 1996). Furthermore, Singapore also established a conducive legal and 
regulatory climate to promote R&D and investments for the industry. Singapore is 
a  signatory  of  the  Patent  Cooperation  Treaty  (PCT),  a  patent  approved  in  the 
country is valid in the other 44 PCT countries including US and Western European 
Countries (Eisenberg, 2001). The formulation of the patenting schemes was one of 
the  masterstroke  step  taken  by  the  Singapore  government  to  enhance  its 
biotechnology industry.  
Malaysia  also  may  draw  some  lessons  from  Cuba’s  experience  in 
developing their  biotechnology industry. Biotechnological development in  Cuba 
was given a substantial boost as a result of an epidemic of dengue fever that broke 
out in 1981.
15 Since then, Cuba was very much focused on developing their health 
care  sector  using  biotechnology.  Modern  biotechnology  was  used  to  facilitate 
product diversification and import substitution especially vaccines. Besides, Cuba 
recognizes that participating in the global market involves forging alliances with a 
wide range of enterprises, especially those that have extensive marketing networks. 
Cuba’s  biotechnology  industry  is  an  example  of  the  importance  of  political 
leadership  on  technological  matters,  domestic  funding  for  research  activities, 
creation of appropriate research institutions, and international alliances for product 
commercialization.  
Unless purposeful action is taken to move towards new activities, Malaysia 
may not be able to overcome the current shortcomings that are backlogging its 
biotechnology  industry.  Hence,  Malaysia  should  seriously  begin  to  focus  on 
solving  the  shortcomings,  especially  in  the  aspect  of  human  capital;  funding; 
commercialisation effort; and technical collaborations to strengthen their industrial 
base. 
The key strategy to foster the development of biotechnology industry is the 
building,  mobilization  as  well  as  the  efficient  utilization  of  scientific  expertise 
through training and education. In this aspect, new curriculum should be developed 
to  cater  the  needs  for  the  required  human  resource.  The  Ministry  of  Science, 
Technology and Innovation (MOSTI) and Ministry of Higher Education (MOHE) 
should work together in developing syllabus and curriculum which is on par with 
the  industry’s  requirement  and  demand.  Graduate  and  undergraduate  training 
underpin the development of in-country capability in the basic biological sciences. 
This is vital in the effort to produce highly qualified and skilled human capital. 
Malaysia  also  should  improve  the  current  post-doctoral  fellowship  system  by 
establishing  considerable  number  of  postdoctoral  fellowships  which  are  a  key 
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should consider recruiting expatriates or professional scientist from foreign land, at 
least for the start, to run the industry along with local manpower. 
Although Malaysia is allocating considerably fair amount of money for the 
research and development purpose, the funding should be focused on the niche area 
of R&D only. Since biotechnology is a high cost venture, there is a special need for 
long  term  planning  in  resource  allocation  for  the  optimal  utilization  of  any 
infrastructure set up. The drying-up of funds at intermediate stages  and limited 
operating budgets are identified as a main cause for low achievements and have 
reduced benefits to a fraction of that expected. In this aspect, Malaysia may follow 
Cuba’s strategy in sectoral funding for research activities. With proper financial 
planning  providing  for  sustained  funding,  R&D  in  Malaysia  can  become  more 
efficient and productive. 
Comparison of the biotechnology development in Malaysia with that of 
Singapore or other countries with active biotechnology networks suggests that the 
absence of collaboration and technical network could have limited the development 
of the industry. Therefore, alliances between the country’s public biotechnology 
R&D agencies and leading private companies which form the pool of scientific 
expertise  in  biotechnology  could  help  in  building  competent  and  competitive 
industry.  So  far,  research  collaborations  in  Malaysia  are  usually  set  up  by 
individual  institutions  with  specialized  local  or  foreign  laboratories  on  specific 
projects only. Hence, there is a pressing need for Malaysia to join as many research 
networks as possible, particularly those involving other developing countries with 
comparable economic status  and similar research interests.  However, this effort 
would  require  continues  public  sector  investments  from  domestic  and  external 
resources,  innovative  funding  mechanisms  from  international  development 
agencies, and involvement of both local private sector companies and transnational 
companies. At the same time, joint ventures or collaborations between local and 
foreign  companies  would  encourage  product  commercialization.  Foreign 
companies may need the market and access to natural resources whilst local firms 
need  access to the technology. The win-win situation will not only enables the 
domestic firm to get full access to the protected knowledge of the foreign firm, but 




Overall, it must be concluded that the biotechnology industry in Malaysia 
is  still  in  the  infant  stage.  Even  though  Malaysia  has  introduced  National 
Biotechnology Policy in 2005, the desired result is yet to be seen as consequences 
of  unfavourable  implementation.  Thus,  Malaysia  needs  to  clearly  redefine  and 
focus on the national agenda with planned strategy to best achieve them. Generally, 
most of the constraints that are holding back the biotechnology sector in Malaysia 
can be resolved with the appropriate policies. Furthermore, biotechnology needs to 
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commercialisation. Manpower training will play a determinant role and emphasis 
should be put on producing high-level scientists rather than technicians. With the 
need  to  extend  these  skills,  the  strategic  planning  will  have  to  make  ample 
provision  for  human  resource  development  with  greater  role  by  MOSTI  and 
MOHE.  It  will  also  be  of  vital  importance  for  Malaysia  to  join  as  many 
biotechnology research networks as possible as we cannot progress in isolation. 
These  networks,  in  addition  to  providing  local  scientists  with  opportunities  for 
training, collaboration in research and the acquisition of new technology at low 
cost,  can  become important technical  forum  to help Malaysia  develop  a  strong 
biotechnology  base.  As  we  move  into  the  future,  proper  funding  and  planned 
investment  in  the  right  biotechnologies  can  help  to  promote  sustainable  use  of 
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